Summary
The 2026 Memorial Sloan Kettering Cardio-Oncology Summit will take place on May 2122, 2026, at the Zuckerman Research Center in New York City and marks the 7th edition of the cardio-oncology conference in NYC.
Organized by Memorial Sloan Kettering Cancer Center, the summit will feature talks by …
Source: Oncodaily
AI News Q&A (Free Content)
Q1: What is the significance of the 2026 Memorial Sloan Kettering Cardio-Oncology Symposium for the cardio-oncology community?
A1: The 2026 Memorial Sloan Kettering Cardio-Oncology Symposium is significant for the cardio-oncology community as it provides a platform for clinicians, researchers, and trainees to engage with cutting-edge science and exchange best practices. The symposium addresses the growing intersection of cancer care and cardiovascular health, focusing on evidence-based strategies for the prevention, early detection, and management of cardiovascular disease in cancer patients.
Q2: How does Memorial Sloan Kettering Cancer Center contribute to cancer research and treatment?
A2: Memorial Sloan Kettering Cancer Center, located in Manhattan, New York, is a leading cancer treatment and research institution. It is one of 72 National Cancer Institute–designated Comprehensive Cancer Centers. The center plays a pivotal role in advancing cancer research and treatment through its integration of clinical care and scientific research, contributing to improved cancer therapies and patient outcomes.
Q3: What are the latest research findings in cardio-oncology from recent scholarly articles?
A3: Recent research in cardio-oncology includes the development of a deep learning framework to identify clonal hematopoiesis of indeterminate potential (CHIP) using cardiac magnetic resonance imaging. This study demonstrated the feasibility of using non-invasive imaging for risk stratification and precision medicine in high-risk cardiovascular populations.
Q4: What innovative diagnostic methods are being explored for neoplasms in cardio-oncology?
A4: Innovative diagnostic methods for neoplasms in cardio-oncology include the use of electrocardiogram (ECG) data combined with machine learning models. This approach is non-invasive and cost-effective, providing significant insights into cardiovascular changes associated with neoplasms and offering potential for integration into broader diagnostic frameworks.
Q5: How is stress being assessed in elderly oncology patients, and what are the implications for cardio-oncology?
A5: Stress in elderly oncology patients is being assessed using multimodal wearable data and multi-instance learning. This method allows for continuous monitoring of psychological stress, which is clinically relevant in cardio-oncology. It highlights the need for integrating stress assessment into cardiotoxicity surveillance to improve patient care.
Q6: What are the advancements in T cell-engaging therapies in oncology, and how do they impact cardio-oncology?
A6: Advancements in T cell-engaging therapies include the transition from bispecific to trispecific antibodies, which promise enhanced tumor selectivity and safety. These developments impact cardio-oncology by potentially reducing cardiovascular risks associated with cancer therapies, though challenges remain in optimizing safety and efficacy.
Q7: What role does the International Cardio-Oncology Society play in the global cardio-oncology community?
A7: The International Cardio-Oncology Society (IC-OS) plays a crucial role in the global cardio-oncology community by providing resources, certifications, and events that promote knowledge exchange and best practices. It supports the integration of cardiovascular care in oncology, aiming to improve patient outcomes worldwide.
References:
- The program features expert-led lectures, interactive case discussions, and a Thursday evening networking and poster session showcasing new research and emerging evidence shaping the future of the field
- Join IC-OS
- Target Audience:This program is intended for cardiologists, internists, hematologists/oncologists, advanced practice providers, nurses, and other allied healthcare professionals who care for patients with cancer or are interested in the evolving field of cardio-oncology
- Page: Memorial Sloan Kettering Cancer Center
- Assessment of Clonal Hematopoiesis of Indeterminate Potential and Future Cardiomyopathy from Cardiac Magnetic Resonance Imaging using Deep Learning in a Cardio-oncology Population
- Published: 2026-01-03
- Explainable machine learning for neoplasms diagnosis via electrocardiograms: an externally validated study
- Published: 2025-11-20
- Stress Estimation in Elderly Oncology Patients Using Visual Wearable Representations and Multi-Instance Learning
- Published: 2026-04-08
